Methods

Patients
Three patients were studied and all fulfilled the clinical diagnostic criteria for GBS." Nerve conduction studies showed the typical features of GBS.'2 Each patient was in the progressive stage Involving Human Subjects.
Drug administration
An intradermal skin test (0-1 mg of OKT3 (Orthoclone OKT*3, 1 mg/ml) was carried out one hour before OKT3 treatment because of a report of anaphylaxis associated with OKT3 (Rice GPA, personal communication). No reactions were seen. Indomethacin 50 mg orally every eight hours was started 12-24 hours before treatment and continued for five days to suppress the adverse reactions to the first few doses of OKT3. For the same reason, each patient received acetaminophen 650 mg every six hours throughout the treatment course and methylprednisolone 100 mg IV immediately before the first dose.
Five milligrams of OKT3 were given daily by intravenous injection for 10 days in two patients and three days in one patient. Each patient received a course of four plasma exchanges of three litres at two day intervals. On plasma exchange days, the OKT3 injection was always given after the procedure. The cause of the side effects of OKT3 is uncertain. Acute headache, fever, nausea and tremulousness is usually seen just with the first two or three doses. Recent evidence suggests that this may be due to the release of large amounts of tumour necrosis factor and gamma interferon into the circulation corresponding to the initial lymphocyte depletion. 25 26 How this relates to aseptic meningitis is unknown. The reactivation of genital herpes in our case 3 was probably related to immunosuppression.
Assessment
OKT3 cannot be recommended as treatment for acute GBS. The clinical disease progressed ast after treatment had induced T-cell depletion in ny two of the three cases. This suggests that Tn a cells, at least at this stage of acute GBS, do not Mis play a major role in the progression of the :ial disease. 
